No apparent alteration of F-18 FDG biodistribution when injected shortly after insulin glargine.
Niederkohr
Ryan D
RD
Division of Nuclear Medicine, Stanford University Medical Center, Stanford, CA 94305-5281, USA. niederkohr@stanford.edu
Quon
Andrew
A
D000328:Adult; D016477:Artifacts; D004347:Drug Interactions; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006801:Humans; D007275:Injections, Intravenous; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D008657:Metabolic Clearance Rate / Q000187:drug effects; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D014018:Tissue Distribution / Q000187:drug effects; D051598:Whole Body Imaging
D007328:Insulin; D049528:Insulin, Long-Acting; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D000069036:Insulin Glargine